- Home
- BPMC vs GH Comparison
BPMC vs GH Comparison
Compare BPMC & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BPMC
- GH
- Stock Information
- Founded
- BPMC 2008
- GH 2011
- Country
- BPMC United States
- GH United States
- Employees
- BPMC N/A
- GH N/A
- Industry
- BPMC Biotechnology: Pharmaceutical Preparations
- GH Medical Specialities
- Sector
- BPMC Health Care
- GH Health Care
- Exchange
- BPMC Nasdaq
- GH Nasdaq
- Market Cap
- BPMC 5.8B
- GH 5.5B
- IPO Year
- BPMC 2015
- GH 2018
- Fundamental
- Price
- BPMC $97.17
- GH $41.72
- Analyst Decision
- BPMC Buy
- GH Strong Buy
- Analyst Count
- BPMC 21
- GH 21
- Target Price
- BPMC $124.05
- GH $52.81
- AVG Volume (30 Days)
- BPMC 973.2K
- GH 2.7M
- Earning Date
- BPMC 05-01-2025
- GH 04-30-2025
- Dividend Yield
- BPMC N/A
- GH N/A
- EPS Growth
- BPMC N/A
- GH N/A
- EPS
- BPMC N/A
- GH N/A
- Revenue
- BPMC $562,121,000.00
- GH $773,996,000.00
- Revenue This Year
- BPMC $44.85
- GH $19.53
- Revenue Next Year
- BPMC $32.06
- GH $21.92
- P/E Ratio
- BPMC N/A
- GH N/A
- Revenue Growth
- BPMC 99.19
- GH 28.20
- 52 Week Low
- BPMC $73.04
- GH $18.01
- 52 Week High
- BPMC $121.90
- GH $52.92
- Technical
- Relative Strength Index (RSI)
- BPMC 59.54
- GH 43.79
- Support Level
- BPMC $87.03
- GH $38.86
- Resistance Level
- BPMC $104.86
- GH $52.92
- Average True Range (ATR)
- BPMC 3.86
- GH 2.91
- MACD
- BPMC 1.24
- GH -0.74
- Stochastic Oscillator
- BPMC 64.38
- GH 20.34
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.